These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34622175)

  • 1. Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza.
    Shibuya M; Tamiya S; Kawai A; Hirai T; Cragg MS; Yoshioka Y
    iScience; 2021 Oct; 24(10):103131. PubMed ID: 34622175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.
    Shibuya M; Aoshi T; Kuroda E; Yoshioka Y
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
    Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
    J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.
    Yamamoto T; Masuta Y; Momota M; Kanekiyo M; Kanuma T; Takahama S; Moriishi E; Yasutomi Y; Saito T; Graham BS; Takahashi Y; Ishii KJ
    Int Immunol; 2019 Feb; 31(2):81-90. PubMed ID: 30535055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
    Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
    Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
    Front Immunol; 2019; 10():3018. PubMed ID: 31998305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Maintenance of the Influenza-Specific Cross-Reactive Memory CD4+ T-Cell Responses Following Repeated Annual Influenza Vaccination.
    Trieu MC; Zhou F; Lartey S; Jul-Larsen Å; Mjaaland S; Sridhar S; Cox RJ
    J Infect Dis; 2017 Mar; 215(5):740-749. PubMed ID: 28007925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
    Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
    J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity.
    Li Z; Zhao Y; Li Y; Chen X
    Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33494477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.
    Okamoto S; Matsuoka S; Takenaka N; Haredy AM; Tanimoto T; Gomi Y; Ishikawa T; Akagi T; Akashi M; Okuno Y; Mori Y; Yamanishi K
    Clin Vaccine Immunol; 2012 Jul; 19(7):979-90. PubMed ID: 22552600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with cell immunoglobulin mucin-1 antibodies and inactivated influenza enhances vaccine-specific lymphocyte proliferation, interferon-gamma production and cross-strain reactivity.
    Soo Hoo W; Jensen ER; Saadat A; Nieto D; Moss RB; Carlo DJ; Moll T
    Clin Exp Immunol; 2006 Jul; 145(1):123-9. PubMed ID: 16792682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-specific T cells as correlate of (cross-)protective immunity against influenza.
    Altenburg AF; Rimmelzwaan GF; de Vries RD
    Vaccine; 2015 Jan; 33(4):500-6. PubMed ID: 25498210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity.
    Laidlaw BJ; Decman V; Ali MA; Abt MC; Wolf AI; Monticelli LA; Mozdzanowska K; Angelosanto JM; Artis D; Erikson J; Wherry EJ
    PLoS Pathog; 2013 Mar; 9(3):e1003207. PubMed ID: 23516357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.
    Ko EJ; Lee Y; Lee YT; Kim YJ; Kim KH; Kang SM
    Antiviral Res; 2018 Aug; 156():107-115. PubMed ID: 29885376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against H5N1 Influenza Virus Induced by Matrix-M Adjuvanted Seasonal Virosomal Vaccine in Mice Requires Both Antibodies and T Cells.
    Cox F; Baart M; Huizingh J; Tolboom J; Dekking L; Goudsmit J; Saeland E; Radošević K
    PLoS One; 2015; 10(12):e0145243. PubMed ID: 26696245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.